ArQule (NASDAQ: ARQL) 11.9% LOWER; filed to offer up to 10,629,000 shares …
Its shares are up 134% year-to-date. The stock soared in late February after the FDA backed its weight loss drug Qnexa. Arena also develops drugs for cardiovascular, central nervous system, inflammatory and metabolic diseases. Up 71% …
VIVUS, Inc. (NASDAQ: VVUS) is on fire again. It was just on Friday that we said that stock options pricing was indicating a $24 breakeven price in April and $28 in June. Amazingly after a huge move already, VIVUS is up double-digit …
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is VIVUS Inc. (VVUS). This Medical – Biomedical/Genetics stock has actually seen loss estimates narrow over the past month for …
VVUS). The firm only has the right to purchase shares in the future through options and contracts. Perry said using the word “may” in the filing raises some red flags. “People hold stock in certain ways for many reasons, be it liquidity, tax ...
Investors can receive FREE Stock Alerts by visiting doubleinstocks.com at the following link: http://www.doubleinstocks.com Today's alerts include: Zamage Digital Art, Inc. (Other OTC: ZMGD.PK), VIVUS Inc. …
Infinera Corporation (NASDAQ: INFN) 13.5% HIGHER; reported Q4 EPS of $0.13, $0.02 better than the analyst …
VVUS) would be smart to sell some shares to raise additional capital ahead of its pending FDA decision in April. Well, some shares sales were sold, but this was from insiders. CEO Leland Wilson sold several batches of shares from …